Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + Relatlimab + Ipilimumab for Renal Cell Carcinoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is comparing two different treatment arms for advanced kidney cancer. One arm will receive three drugs every 4 weeks while the other arm will receive two drugs every 3 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service